Supernova may have caused an ice age: Study
A new study revealed the timing of the Vela supernova aligned with a period known as the Younger Dryas, when global temperatures dropped and ice sheets began advancing.
Scientists believe the exploding star bombarded the planet with radiation that severely damaged the ozone layer based on tree ring records showing a spike in radioactive carbon-14, which indicates atmospheric radiation increased.
Bobcat Fever: Deadly disease that kills cats in the Midwest
Ice cores also revealed a decrease in methane concentrations, and archaeological sites across North America have 'black mat' deposit,s and fossil records show the extinction of mammals, including the mammoth and saber-toothed cats.
Without protection from the ozone layer, harmful ultraviolet radiation would reach the surface of the Earth, triggering massive wildfires and causing DNA damage to plants and animals.
The study also found several other potential connections between supernova incidents and changes in the Earth's climate.
Toxic-exposed veterans: Bill calls for more research on health issues among families
Other scientists are skeptical about the results, pointing out alternative explanations, including ocean circulation disruptions from freshwater floods, solar storms spiking carbon-14 and mammal extinctions due to asteroid impacts or human hunting.
If supernovas are the cause, it could be something the Earth faces again. Several nearby stars could become future supernovas, including a red giant called Betelgeuse that may explode within the next million years.
A supernova might not necessarily cause a mass extinction, but it could still have impacts on the planet's atmosphere and climate.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock
Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ('ETST' or the 'Company'), a strategic holding company focused on acquiring and scaling high-potential businesses, today announced that its Board of Directors has approved a reduction of the Company's authorized shares of common stock from 350 million to 300 million. This strategic reduction in authorized shares of common stock is a direct reflection of the Board's confidence in the Company's current trajectory and its commitment to protecting long-term shareholder value. "This move by the Board of Directors aligns with our current goal of reducing the share count." said Giorgio R. Saumat, CEO of ETST. "It sends a clear signal to the investment community: we are confident in our financial health, strategic plan, and we are committed to preventing unnecessary shareholder dilution.' With the Company's outstanding share count at approximately 294.3 million, the Board determined that the previous authorization level of 350 million shares was no longer necessary given the Company's direction and financial planning. About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company's current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC ('Mister Meds'), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef. To learn more, please visit: LLC. based in Miami, Florida, is a fully licensed compounding pharmacy authorized to fulfill prescriptions in the following states and territories: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Wisconsin and Puerto Rico. RxCompound is actively pursuing licensure in the remaining U.S. states. To learn more please visit: MisterMeds, LLC. Mister Meds, acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound. To learn more please visit: Peaks Curative, LLC. Peaks is a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds. The platform operates in states where either pharmacy is licensed. Through the development of its own healthcare provider network, and ongoing licensure expansion for both pharmacies, Peaks aims to offer services nationwide. In addition, the company has recently expanded into the veterinary market through the acquisition of To learn more please visit: Las Villas Health Care, Inc. Las Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education—empowering you to take control of your health with confidence. To learn more please visit: LLC. Doconsultation was born with a passion to modernize the availability and delivery of home therapies. DOConsultations providers tailor a medication plan around your health and wellness goals and follow up with our patients to ensure results, while our partner pharmacies conveniently ship directly to your door. To learn more please visit: Avenvi, LLC. Avenvi is a diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company's ongoing $5 million share repurchase program. To learn more please visit: MagneChef MagneChef is a direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property. In addition, the company has recently expanded into the premium American-made BBQ tool brand market through the acquisition of BBQraft. To learn more please visit: About Earth Science Foundation, Inc. Earth Science Foundation Inc. a 501(c)(3) nonprofit organization incorporated on February 11, 2019, is the charitable arm of ETST. ESF accepts grants and donations to assist individuals who need financial support for prescription costs at both RxCompound and Mister Meds. SAFE HARBOR ACT: Forward-Looking Statements. Except for historical information, the matters discussed herein may be considered 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as 'expect,' 'expectation,' 'believe,' 'anticipate,' 'may,' 'could,' 'intend,' 'belief,' 'plan,' 'estimate,' 'target,' 'predict,' 'likely,' 'seek,' 'project,' 'model,' 'ongoing,' 'will,' 'should,' 'forecast,' 'outlook' or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company's actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Company Contact:Giorgio R. SaumatCEO and Chairman of the Board(305) 724-5684IR@
Washington Post
2 hours ago
- Washington Post
NASA's Webb telescope finds a new tiny moon around Uranus
NEW YORK — The Webb Space Telescope has spotted a new tiny moon orbiting Uranus . The new member of the lunar gang , announced Tuesday by NASA, appears to be just six miles (10 kilometers) wide. It was spotted by the telescope's near-infrared camera during observations in February.
Yahoo
2 hours ago
- Yahoo
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc.
